Cagrilintide vs retatrutide comes down to one pathway versus three. Cagrilintide mimics the satiety hormone amylin, while retatrutide hits GLP-1, GIP and glucagon receptors. Neither is FDA-approved yet. TelosRX answers the top questions below.
Search interest in "cagrilintide vs retatrutide" has climbed this month. That makes sense. Both are next-wave weight-management drugs, and both get stacked together in online forums.
Our clinical team reviewed the most common questions. Every answer below is drawn from published trial data, not forum lore.
What Is Cagrilintide?
Cagrilintide is a long-acting amylin analog from Novo Nordisk. Amylin is a hormone your pancreas releases alongside insulin after meals. It helps you feel full and slows how fast your stomach empties.
Cagrilintide is given as a once-weekly injection in trials. It's best known as half of CagriSema, a combination with semaglutide. Our CagriSema Q&A covers that pairing in depth.
What Is Retatrutide?
Retatrutide is an investigational once-weekly injection from Eli Lilly. It's a "triple agonist," meaning it switches on three hormone receptors at once:
- GLP-1: dampens appetite and slows digestion.
- GIP: a second gut hormone that boosts the GLP-1 effect.
- Glucagon: may raise energy use and lower liver fat.
It's currently in the phase 3 TRIUMPH program. See our breakdown of retatrutide clinical trial results for the full trial list.
How Do Cagrilintide and Retatrutide Work Differently?
They don't compete for the same receptor. That's the key point. Cagrilintide works through amylin and calcitonin receptors. Retatrutide works through incretin and glucagon receptors.
| Feature | Cagrilintide | Retatrutide |
|---|---|---|
| Drug class | Long-acting amylin analog | GLP-1/GIP/glucagon triple agonist |
| Developer | Novo Nordisk | Eli Lilly |
| Receptors | Amylin and calcitonin | GLP-1, GIP, glucagon |
| Dosing in trials | Once weekly, injection | Once weekly, injection |
| Approximate half-life | About a week | About 6 days |
| Best-known pairing | CagriSema (with semaglutide) | Studied mainly on its own |
| FDA status | Not FDA-approved | Not FDA-approved |
Want the bigger picture on these two hormone families? Our guide to amylin vs GLP-1 explains how they overlap.
What Did the Weight Trials Show for Each Drug?
The data come from different trials, so a true head-to-head doesn't exist. Here's what each program reported.
Retatrutide: In the phase 2 trial published in NEJM, the 12 mg group saw a mean body-weight change of −24.2% at 48 weeks. Placebo was −2.1%.
Cagrilintide: In the REDEFINE 1 trial in NEJM, cagrilintide alone produced a mean change of −11.8% at 68 weeks. CagriSema reached −20.4%, versus −3.0% on placebo.
So retatrutide alone posted larger averages than cagrilintide alone. But trial length, doses and populations differed. These are group averages, and individual results vary.
Who Was Studied in These Trials?
Trial populations shape what results mean for you. Here's who enrolled:
- Retatrutide phase 2: 338 adults with obesity, or overweight plus a weight-related condition. People with diabetes were excluded.
- REDEFINE 1: 3,417 adults with obesity, or overweight plus a related condition, without diabetes.
- The combination study: diet-induced obese male rats, not people.
Results in people with type 2 diabetes are often smaller. Separate trials are studying that group for both drugs.
Why Do Researchers Want to Combine Amylin and Incretin Drugs?
Appetite runs on more than one signal. GLP-1 drugs quiet hunger through one set of brain circuits. Amylin works through a partly separate set in the brainstem.
Hitting both may add up. That's the logic behind CagriSema, and behind the newer retatrutide-plus-cagrilintide idea. It's also why drug makers are now designing single molecules that hit several receptors at once.
Has Anyone Studied Cagrilintide and Retatrutide Together?
Yes, but only in animals so far. A 2026 study in Nature Metabolism gave the pair to obese male rats daily.
The combination cut body weight and food intake more than either drug alone. It also beat matched combinations that used semaglutide or tirzepatide. Cholesterol, triglycerides and insulin levels improved too.
This is preclinical research. Rat results often don't carry over to people. No human trial of this "four-receptor stack" has been published.
How Do the Side Effects Compare?
Both drugs mainly cause gastrointestinal effects in trials. That fits their shared job of slowing digestion and curbing appetite.
- Common to both: nausea, vomiting, diarrhea, constipation and reduced appetite.
- Retatrutide: the phase 2 trial also reported dose-related heart-rate increases.
- Cagrilintide: GI effects were generally mild to moderate and eased over time.
Stacking two appetite-suppressing drugs could pile up those effects. That's one reason combining them outside a trial isn't a safe DIY project.
Can You Get Cagrilintide or Retatrutide Today?
Not legitimately. Neither drug is FDA-approved, and neither can be prescribed outside a clinical trial. Products sold online as "reta" or "cagri" are unregulated research chemicals.
Those vials aren't checked for purity, sterility or dose. They're not a safe shortcut to next-generation results.
Want an option you can start now? Tirzepatide and semaglutide are available today with a provider-issued prescription. Compare TelosRX GLP-1 options, subject to medical approval by a licensed provider.
What Should You Consider Instead Right Now?
Tirzepatide already targets two of retatrutide's three receptors: GLP-1 and GIP. Semaglutide is the GLP-1 half of CagriSema. Both have years of human safety data.
TelosRX runs an asynchronous telehealth process. You complete an online intake, and a licensed provider reviews it on their schedule. Compounded versions are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.
Frequently Asked Questions
Is retatrutide stronger than cagrilintide?
In published trials, retatrutide alone produced larger average weight changes than cagrilintide alone. Retatrutide reached about −24% at 48 weeks in phase 2, while cagrilintide alone reached about −12% at 68 weeks. The trials differed in design, so this isn't a true head-to-head comparison.
Can you stack cagrilintide and retatrutide?
The combination has only been tested in rats. A 2026 Nature Metabolism study found greater weight and food-intake reductions than either drug alone. No human trial has been published. Neither drug is FDA-approved, so stacking them outside a trial means using unregulated products with unknown risks.
What is the half-life of cagrilintide vs retatrutide?
Both are built for once-weekly dosing. Cagrilintide's half-life is roughly a week, and retatrutide's is about six days, based on early clinical studies. Long half-lives mean steadier drug levels between doses. They also mean side effects can take longer to fade after a dose.
Is cagrilintide a GLP-1?
No. Cagrilintide is an amylin analog. It acts on amylin and calcitonin receptors, not the GLP-1 receptor. That's why researchers pair it with GLP-1 drugs like semaglutide. The two pathways reduce appetite in different ways, and the effects appear to add together in trials.
When will retatrutide be available?
Eli Lilly hasn't announced an FDA approval date. Retatrutide is still in phase 3 trials, and approval timelines depend on the full data package and FDA review. Until then, it's only available inside clinical trials. Online "research" products are not legitimate prescriptions.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.